An Early Stage Study to Evaluate Oba01 for Injection in Patients With DR5 Positive LA/mNSCLC

Status:
Recruiting

Trial end date:
2026-07-01

Target enrollment:

Participant gender:

This study will evaluate the safety, tolerability, pharmacokinetics and efficacy of Oba01 for injection in patients with DR5 positive LA/mNSCLC.

Phase 1

Lu Shun